Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
13.118 / 17.032
#104937

Re: Farmas USA

SYN

Dentro a 0.51

Edito: me las han dado a 0.509

#104938

Re: Farmas USA

ACAD

In 28,40

#104939

Re: Farmas USA

CRIS

Mirandola hoy al cambio $/€  las promedio a 1.2354

Hoy +8%

#104940

Re: Farmas USA

CRIS

Se me han escapado.

Subiendo un 8%

#104941

Re: Farmas USA

Perdón! Durante unos minutos está la noticia abierta a todo el mundo, luego ya solo con suscripción... Pero olvídate porque estoy viendo que esa noticia viene de finales de 2016...old news!

DVAX

Dentro a 15

TSRO

Dentro a 65

 

#104942

Re: Farmas USA

dentro a 2,35

SGYP

#104943

Re: Farmas USA

TSRO
Te acompaño a 64,65

#104944

Re: Farmas USA

TSRO

Por si alguien no ha visto la noticia

 

Following its introduction in late November 2017, TESARO estimates that at least 7,000 doses of VARUBI injectable emulsion have been administered to patients receiving emetogenic chemotherapy in the United States. Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions have been reported in the postmarketing setting, some requiring hospitalization. These reactions have occurred during or soon after the infusion of VARUBI injectable emulsion. Most reactions have occurred within the first few minutes of administration.

 

Patient safety is a paramount priority for TESARO. In its commitment to ensuring patients and healthcare professionals are aware of the label update, TESARO has issued a Dear Healthcare Professional (DHCP) letter. This letter, as well as the updated full prescribing information, has been posted on the VARUBI website (www.varubirx.com). Additionally, members of the TESARO field force will be calling on healthcare professionals to communicate this important new safety information.

 

http://stocknewsflow.com/1491576_000110465918002251_0001104659-18-002251ppp3

«Después de nada, o después de todo/ supe que todo no era más que nada.»

Te puede interesar...
  1. Primeras dudas sobre la 'Trumponomics', ¿corrección o toma de beneficios?
  2. Nvidia bate expectativas pero decepciona. Insiders reafirman su posición